⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083236 | 0.67 | KDM4E (0.43) | — | |
| SCHEMBL1815329 | 0.67 | — | — | |
| SCHEMBL16412018 | 0.65 | — | — | |
| SCHEMBL4887163 | 0.64 | — | — | |
| SCHEMBL1817093 | 0.64 | — | — | |
| SCHEMBL945843 | 0.60 | — | — | |
| SCHEMBL1818847 | 0.60 | — | — | |
| SCHEMBL4275644 | 0.60 | — | — | |
| SCHEMBL279387 | 0.60 | — | — | |
| SCHEMBL1995598 | 0.60 | HDAC8 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | claimed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | claimed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | claimed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | claimed |
| CN-114901284-A | Methods of treating cancer in patients identified by biomarkers with cyclin dependent kinase 7(CDK7) inhibitors | 希洛斯医药品股份有限公司 | 2022-08-12 | — | — | CN | claimed |
| WO-2021087138-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | claimed |
| EP-3484871-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | claimed |
| WO-2018013867-A1 | INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) | MARINEAU JASON J (US) | 2018-01-18 | — | — | WO | claimed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | claimed |
| EP-2867236-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | Pfizer Inc. (US) | 2015-05-06 | — | — | EP | claimed |
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | claimed |
| WO-2014001973-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2014-01-03 | — | — | WO | claimed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | claimed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | claimed |
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | claimed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230000870-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-01-05 | — | — | US | disclosed |
| CN-114901284-A | Methods of treating cancer in patients identified by biomarkers with cyclin dependent kinase 7(CDK7) inhibitors | 希洛斯医药品股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20210290631-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2021-09-23 | — | — | US | disclosed |
| US-11058689-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical | LES LABORATOIRES SERVIER (FR) | 2021-07-13 | — | — | US | disclosed |
| WO-2021087138-A1 | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20200261464-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2020-08-20 | — | — | US | disclosed |
| US-10688101-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATORIES SERVIER (FR) | 2020-06-23 | — | — | US | disclosed |
| US-20190192528-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2019-06-27 | — | — | US | disclosed |
| EP-3484871-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| US-10265323-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-04-23 | — | — | US | disclosed |
| WO-2018013867-A1 | INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) | MARINEAU JASON J (US) | 2018-01-18 | — | — | WO | disclosed |
| US-20170202851-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-07-20 | — | — | US | disclosed |
| US-9642855-B2 | Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9598427-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-03-21 | — | — | US | disclosed |
| EP-2829539-B1 | New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150313907-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-11-05 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9108983-B2 | Pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2015-08-18 | — | — | US | disclosed |
| EP-2867236-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | Pfizer Inc. (US) | 2015-05-06 | — | — | EP | disclosed |
| US-20150031673-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2015-01-29 | — | — | US | disclosed |
| EP-2829539-A1 | New pyrrole derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2015-01-28 | — | — | EP | disclosed |
| US-20140221354-A1 | IMIDAZO [1,2-a]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM TECHNOLOGY TRANSFER GMBH (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2691392-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | EMBLEM Technology Transfer GmbH (DE) | 2014-02-05 | — | — | EP | disclosed |
| WO-2014001973-A1 | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | PFIZER INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | disclosed |
| US-20120291159-A1 | Azoline Compounds for Combating Invertebrate Pests | BASF SE (DE) | 2012-11-15 | — | — | US | disclosed |
| WO-2012130322-A1 | IMIDAZO [1,2-A]PYRIDINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | disclosed |
| WO-2011073444-A2 | AZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057892-A1 | 2,3-DIHYDROBENZOXAZINE AND 2,3-DIHYDROBENZOTHIAZINE DERIVATES AS HIF-INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | ELARA PHARMACEUTICALS GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |